Thompson Elizabeth H.Z. 4

What Happened

• Elizabeth H.Z. Thompson, EVP & Head of R&D at ACADIA Pharmaceuticals, had 32,272 restricted stock units convert to common shares on July 29, 2026 and sold 16,558 shares in open-market transactions on July 30, 2026 for total proceeds of about $432,663. The filing also reports a same-day derivative disposal of 32,272 shares at $0 in connection with the conversion/vesting.

Key Details

• Transaction dates and prices:
  • 2026-07-29: 32,272 RSUs converted/exercised (reported as derivative M). Acquisition price reported as N/A; a derivative disposition of 32,272 shares is also reported at $0.
  • 2026-07-30: Open-market sale of 16,508 shares at $26.13 each — proceeds $431,354.
  • 2026-07-30: Open-market sale of 50 shares at $26.17 each — proceeds $1,309.
  • Combined open-market sale proceeds ≈ $432,663.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each restricted stock unit (RSU) equals a contingent right to one share.
  • F2: The sales were described as mandatory to cover withholding taxes tied to RSU vesting and intended to comply with Rule 10b5-1(c) requirements.
  • F3: Vesting schedule: 50% of the RSUs vested on July 29, 2026; remaining 25% vest on July 29, 2027 and July 29, 2028.
• Filing/timeliness: Form filed on 2026-07-31 covering transactions on 7/29–7/30; filing appears timely.

Context

• This was not a purchase — the activity reflects RSU vesting/conversion and subsequent sales largely to satisfy tax withholding obligations, per the filing. The reported derivative entries reflect settlement/conversion of RSUs rather than a traditional option purchase. Such mandatory tax-related sales are routine and do not necessarily signal insider sentiment about the company.